Trial Profile
A Four-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of AF-219 in Female Subjects With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Gefapixant (Primary)
- Indications Interstitial cystitis; Pain
- Focus Therapeutic Use
- Sponsors Afferent Pharmaceuticals
- 06 Aug 2020 Status changed from completed to discontinued.
- 09 Oct 2015 Results presented at the 45th Annual Meeting of the International Continence Society
- 26 Feb 2015 According to an Afferent Pharmaceuticals media release, the results of this trial were presented at the 2015 Society of Urodynamics, Female Pelvic Medicine and Urogential Reconstruction Meeting.